vTv Therapeutics Inc. (VTVT)
VTVTNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$21.18
+0.0450 (+0.21%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $84.96m
- P/E
- –
- EPS, last 4 quarters
- $-0.9200
- Dividend yield
- –
- Day range
- –
- 52-week range
- $20.56 to $44.00
- Average volume
- 32.3k
- Previous close
- $21.14
Analysts
5 coveringBuy5 buy, 0 hold, 0 sell
Targets a year out average $54.25, +156.1% from here
Earnings
next estimate $-1.14Next report
Dec 2025
+40.8%
Mar 2026
+385.3%
Jun 2026
-40.0%
Sep 2026
+12.2%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | $36.84m | – |
| Gross profit | – | – | $36.84m | – |
| Operating income | -$10.70m | -$7.88m | $23.26m | -$13.93m |
| Net income | -$8.70m | -$7.14m | $24.13m | -$13.05m |
News
8 latest- vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 HypoglycemiaMarketBeat · Oct 20, 2026
- VTv's HPPD Receives FDA Orphan Drug Status For Sickle Cell Disease RTTNews · Oct 8, 2026
- vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable Zacks · May 15, 2026
- Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?Zacks · Apr 20, 2026
- Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a BetZacks · Apr 2, 2026
- Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to TradeZacks · Mar 17, 2026
- Evercore ISI Group Initiates Coverage of vTv Therapeutics (VTVT) with Outperform RecommendationFintel · Mar 12, 2026
- VTv Therapeutics Posts Wider FY25 Loss, Advances Phase 3 CATT1 Trial For Type 1 Diabetes RTTNews · Mar 11, 2026
The company
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, a potential first-in-class oral glucokinase activator being investigated in a U.S. Phase 3 study for the treatment of T1D. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- vtvtherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.